ATS: Pulmonary Arterial Registry Risk Algorithms Improve Upon Clinical Trial Enrichment Methodology

Scott JV, Kanwar M, Garnett C, Stockbridge N, Benza RL. B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT: American Thoracic Society; 2020:A2920-A. Introduction: Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. Clinical trials for PAH now use time to morbidity/mortality event (clinical worsening) as the primary endpoint instead of six-minute walk distance (6MWD). These […]


J.V. Scott, L.C. Lohmueller, Kraisangka J, M.K. Kanwar , R.L. Benza. Chest, Volume 156, Issue 4, Supplement, 2019, Pages A1173-A1174, ISSN0012-3692 PURPOSE: Invasive hemodynamics are a valuable component of risk assessment in pulmonary arterial hypertension (PAH). Although several commonly obtained variables are highly associated with survival, the full breath of alternative hemodynamic assessments (HA) and […]

ATS: Upfront Combination Versus Monotherapy in Pulmonary Arterial Hypertension (PAH): Can Advanced Risk Stratification Tell Us the Real Benefit?

J.V. Scott, L.C. Lohmueller , C.G. Garnett , M.K. Kanwar , R.L. Benza. A105 GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH / Poster Discussion Session / American Thoracic Society 2019;199:A7346 Rationale: The Registry to Evaluate Early and Long-Term PAH Disease Management recently updated their linear multivariable risk-stratification tool (REVEAL 2.0). Our ongoing study aims […]

ISHLT: Derivation of a Bayesian Network Model from an Existing Risk Score Calculator for Pulmonary Arterial Hypertension

Purpose: We propose an alternative approach to the extensively validated REVEAL risk score calculator using Bayesian network (BN) modeling. We derived a BN model with the same variables and discretization cut points as the REVEAL risk score calculator and data from the REVEAL registry. This study compared the performance and relative impact of the variables […]